INDUSTRIAL PARTNERSHIP AGREEMENTS

An objective of the BIOMUNEX’s strategy aims to establish collaborations and partnerships with major industrial partners either to develop new bi- and multi-specific antibodies using its proprietary BiXAb® platform based on the partner’s existing library or to identify new therapeutically valuable targets, for which BIOMUNEX will generate and optimize bi- or multi-specific antibodies.

BIOMUNEX’s technology will generate antibodies with excellent drug-like properties and high production yields. BIOMUNEX can complete the necessary BiXAb® characterization, design and validation in in vitro and in vivo models and beyond, in order to accommodate partners by taking projects up to regulatory preclinical studies.

The BiXAb® platform has been externally validated by deals with SANOFI and ONWARD Therapeutics:

• 2019 – Out-licensing agreement with SANOFI focused on generation and optimization of bi- and multi-specific antibody therapeutics.
  Under this agreement, SANOFI has access to a part of BIOMUNEX’ technology for the generation, optimization, and development of bi- and multi-specific therapeutic antibodies. To date, BIOMUNEX has received a significant upfront payment that has allowed it to pursue its development. BIOMUNEX is also eligible for clinical, regulatory, and commercial development milestones, while SANOFI will be responsible for research, development, manufacturing and commercialization activities worldwide.

• 2021 – Worldwide out-licensing and co-development agreement with ONWARD Therapeutics for one of proprietary bispecific antibody programs of BIOMUNEX.
  This collaboration covers the preclinical and clinical co-development of the antibody for the treatment of selected solid tumors and hematological malignancies.
  BIOMUNEX has already received an upfront payment, but also the first clinical milestone thanks to the start of the Phase 1, and a strategic investment from ONWARD Therapeutics. BIOMUNEX is also eligible for clinical, regulatory, and commercial development milestones and royalties, as well as other payments.

• 2024 – Global licensing agreement with IPSEN for the development of a first-in-class MAIT cell engager in immuno-oncology.

  With this collaboration, Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a preclinical novel T cell engager (TCE) with first-in-class potential. BMX-502 is a bispecific antibody capable of engaging and activating MAIT cells to target the GPC3 tumor antigen, a clinically validated target highly expressed across several types of cancers, and to kill cancer cells.

  Under the terms of this agreement, Biomunex will complete the IND-enabling package while Ipsen will assume responsibility for Phase I preparation activities, including submission of the Investigational New Drug (IND) application, and all subsequent clinical development and global commercialization activities.

  Biomunex is eligible to receive up to $610 million, including upfront, contingent upon successful development, regulatory and commercial milestones, in addition to tiered global royalties on sales